Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Annual Bonus Plan (DABP) post-tax awards for the 2013 bonus year.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. Instead, it details specific performance thresholds used for executive compensation vesting:
- Adjusted Free Cash Flow Thresholds: Vesting ranges from 0% (below £13.68bn) to 100% (at £16.22bn).
- Share Price: Co-Investment Shares were acquired on March 20, 2014, at an Ordinary Share price of £16.2954.
- Executive Award Details: Ms. C. Thomas was granted 2,534 Co-Investment Shares. Potential Matching Awards range from nil to 845 shares based on Total Shareholder Return (TSR) and nil to 1,689 shares based on cash flow and R&D metrics.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It reports a specific transaction: the acquisition of Co-Investment Shares by Ms. C. Thomas on March 20, 2014, following the announcement of 2013 bonus awards on February 13, 2014.
Guidance, Outlook, and Risks
Performance Measures and Outlook: The filing outlines the three-year performance period (January 1, 2014, to December 31, 2016) for executive awards, linking them to:
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies (including AstraZeneca, Pfizer, and Novartis). Vesting is 0% if ranked 6th or below, 44% if ranked 5th, and maximum if ranked 1st-3rd.
- Adjusted Free Cash Flow: Specific monetary targets set for vesting.
- R&D New Product Performance: Targets are undisclosed due to commercial sensitivity but will be disclosed at the end of the performance period.
Risks and Contingencies: The primary risk highlighted is the potential lapse of conditional awards if performance thresholds are not met. Dividends accrue on conditionally awarded shares but only vest if the underlying shares vest.
Key Facts for Investor Verification
- Verify the company's actual Adjusted Free Cash Flow performance against the £13.68bn to £16.22bn vesting thresholds outlined for the 2014-2016 period.
- Monitor GSK's Total Shareholder Return ranking relative to the specified comparator group of 10 pharmaceutical peers.
- Note that specific R&D new product targets are currently undisclosed and will only be revealed at the end of the three-year performance period.
- Confirm the share price of £16.2954 used for the March 20, 2014, Co-Investment Share acquisition.